Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Thursday, 05 / 13 / 2021




Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis

Mengdi Jin1,2, Qiong Yu2, Yahui Liu1, Weiling Xu3, Xueqi Fuand Bai Ji1,*

1  Department of Hepatobiliary and Pancreatic Surgery, the First Hospital of Jilin University, Changchun, Jilin, China
2  Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin, China
3  Edmond H. Fischer Signal Transduction Laboratory, College of Life Sciences, Jilin University, Changchun, Jilin, China
*Correspondence to: Bai Ji, Department of Hepatobiliary and Pancreatic Surgery, the First Hospital of Jilin University, No. 71, Xinmin Street, Changchun, Jilin 130021, China. ORCID: . Tel: +86-431-81875160, E-mail:  This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(2):149-159 DOI: 10.14218/JCTH.2020.00125
Received: November 22, 2020 Accepted: February 21, 2021 Published online: March 8, 2021


Background and Aims: To compare the efficacy and safety of physical thermal ablation (PTA), including radiofrequency ablation (RFA) and microwave ablation (MWA), combined with sorafenib and physical thermal ablation alone for the control and treatment of hepatocellular carcinoma (HCC) according to the available literature.

Methods: Comprehensive searches were performed on PubMed, Embase, CNKI, the Cochrane Library, China Biomedical Literature Database (known as CBM), Weipu Journal, and Wanfang Database. Meta-analysis was performed using Revman 5.3 software.

Results: A total of 15 studies, consisting of 2,227 HCC patients, were selected and included in this meta-analysis. Compared with the RFA-alone group, the patients in the RFA+sorafenib group had longer 1-, 2-, and 3-year overall survival (all p<0.05), better overall efficacy (p<0.0001), longer radiofrequency interval (p<0.001), and lower 2-year recurrence rate (p=0.02). The 1-year overall survival (p=0.003) and overall efficacy (p=0.002) of the MWA+sorafenib group were also higher than those of the MWA-alone group. The incidences of adverse reactions in the RFA+sorafenib group, such as hand-foot skin reactions (p<0.001), diarrhea and constipation (p=0.0001), hypertension (p=0.009), and alopecia (p<0.001), were significantly higher than those in the RFA-alone group.

Conclusions: RFA or MWA combined with sorafenib has produced a better therapeutic effect on HCC than physical thermal ablation alone; however, adverse reactions have been obvious. It is necessary to evaluate the safety of combination therapy, and pay close attention to the adverse reactions that develop in patients.


Physical thermal ablation, Radiofrequency ablation, Microwave ablation, Sorafenib, Hepatocellular carcinoma, Meta-analysis

Journal of Clinical and Translational Hepatology 2021 vol. 9, 149-159  [ Html  ] [ PDF Full-text ]

© 2021 Authors. This is an Open Access article distributed under the terms of the  Creative Commons Attribution-Noncommercial 4.0 License(CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


You are here: Home